Interestingly, while CSF Aβ1–42 levels and p-Tau 181/Tau ratio were also cross-sectionally associated with the MMSE score at the diagnosis, only p-PKR was determined as a biomarker of cognitive decline during the progression of AD. This evidence concerns the gene MAPT and Alzheimer disease.